Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks

PACE - Pacing and Clinical Electrophysiology

Volumn 34, Issue 12, 2011, Pages 1600-1606

  Bunch, T Jared ^a   Mahapatra, Srijoy ^b   Murdock, David ^c   Molden, Jamie ^d   Weiss, J Peter ^a   May, Heidi T ^a   Bair, Tami L ^a   Mader, Katy M ^a   Crandall, Brian G ^a   Day, John D ^a   Osborn, Jeffrey S ^a   Muhlestein, Joseph B ^a   Lappe, Donald L ^a   Anderson, Jeffrey L ^a  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Aspirus Wausau Hospital   (United States)

^d Dixie Regional Medical Center   (United States)

Author keywords

Heart failure; ICD shocks; Ischemia; Sodium current; Ventricular tachycardia

Indexed keywords

ACETAZOLAMIDE; AMIODARONE; ATORVASTATIN; BUMETANIDE; CARVEDILOL; CLOPIDOGREL; DIGOXIN; ENALAPRIL; FUROSEMIDE; INSULIN; LIDOCAINE; LISINOPRIL; LOSARTAN; METOLAZONE; METOPROLOL; MEXILETINE; RANOLAZINE; ROSUVASTATIN; SIMVASTATIN; SOTALOL; SPIRONOLACTONE; VALSARTAN; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEFIBRILLATOR; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOGLYCEMIA; MALE; QRS COMPLEX; QT INTERVAL; TREATMENT OUTCOME;

EID: 83555164819     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2011.03208.x     Document Type: Article

References (15)

1. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, et al,. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004; 110: 2591-2596. (Pubitemid 39453007)
2. Schaumann A, von zur Muhlen F, Herse B, Gonska BD, Kreuzer H,. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: A prospective study including 200 patients. Circulation 1998; 97: 66-74. (Pubitemid 28036156)
3. Aliot EM, Stevenson WG, Almendral-Garrote JM, Bogun F, Calkins CH, Delacretaz E, Della Bella P, et al,. EHRA/HRS expert consensus on catheter ablation of ventricular arrhythmias: Developed in a partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm 2009; 6: 886-933.
4. Stevenson WG, Soejima K,. Catheter ablation for ventricular tachycardia. Circulation 2007; 115: 2750-2760. (Pubitemid 46842792)
5. Zhao G, Walsh E, Shryock J, Messina E, Wu Y, Zeng D, Xu X, et al,. Anti-adrenergic and hemodynamic effects of ranolazine in conscious dogs Zhao, anti-adrenergic effect of ranolazine. J Cardiovasc Pharmacol 2011 (in press).
6. Reddy BM, Weintraub HS, Schwartzbard AZ,. Ranolazine: A new approach to treating an old problem. Tex Heart Inst J 2010; 37: 641-647.
7. Morita N, Lee JH, Xie Y, Sovari A, Qu Z, Weiss JN, Karagueuzian HS,. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J Am Coll Cardiol 2011; 57: 366-375.
8. Kloner RA, Dow JS, Bhandari A,. First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. J Cardiovasc Pharmacol Ther 2011; 16: 192-196.
9. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, et al,. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110: 904-910. (Pubitemid 39136212)
10. Nieminen T, Nanbu DY, Datti IP, Vaz GR, Tavares CA, Pegler JR, Nearing BD, et al,. Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model. Heart Rhythm 2011; 8: 608-614.
11. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C,. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010; 56: 1216-1224.
12. Murdock DK, Kaliebe J, Overton N,. Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: A case report. Pacing Clin Electrophysiol 2008; 31: 765-768. (Pubitemid 351749321)
13. Timmis AD, Chaitman BR, Crager M,. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27: 42-48. (Pubitemid 41785931)
14. Chisholm JW, Goldfine AB, Dhalla AK, Braunwald E, Morrow DA, Karwatowska-Prokopczuk E, Belardinelli L,. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 2010; 33: 1163-1168.
15. Jerling M, Abdallah H,. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther 2005; 78: 288-297. (Pubitemid 41254113)